CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 131 enrolled
Drug / intervention
LY3857210 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05620576
NCT05620576Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Diabetic Peripheral Neuropathic Pain

Eli Lilly and Company·interventional·Posted Nov 17, 2022·Updated Aug 7, 2024

In Brief

A Phase 2 clinical trial evaluating LY3857210 and Placebo for Diabetic Peripheral Neuropathic Pain. Completed, enrolled 131 participants across 30 sites in 2 countries.

Detailed Summary

This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathic Pain
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedNov 17, 2022
Enrollment StartNov 14, 2022
Primary CompletionJul 19, 2023
Study CompletionAug 1, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.6 years ago

Interventions

LY3857210drug

Administered orally

Placebodrug

Administered orally